Polyurethane-biomacromolecule combined foam dressing containing asiaticoside: fabrication, characterization and clinical efficacy for traumatic dermal wound treatment

Int J Biol Macromol. 2020 Jan 15:143:510-520. doi: 10.1016/j.ijbiomac.2019.10.166. Epub 2019 Nov 25.

Abstract

Polyurethane combined (PUC) foam dressings with various biomacromolecules were fabricated with the adsorption of asiaticoside and silver nanoparticles for traumatic wound treatment. Biomacromolecules had varying effects on physicochemical and mechanical properties of PU foam. With 2% incorporation, starches, high molecular weight chitosan and gelatin provided stiffer and more porous foams while carboxymethylcellulose had the highest compression strength but the lowest water vapor transmission. High water absorption was from foams with carboxymethylcellulose, alginate, hydroxypropyl methylcellulose and low molecular weight chitosan. Increasing the concentrations up to 12% had more prominent effect. However, powdery surface was noticed with poorer tensile properties that 6% incorporation was selected. FTIR spectra and DSC thermograms suggested interaction of PU formulation with biomacromolecules. EDS analysis confirmed existence of active compounds while acceptable stability was from sterilized PUC foam with alginate. On healthy volunteers, this selected foam dressing caused no skin irritation and retained moisture comparable to commercial product. In patients with traumatic dermal wounds, healing improvement with shorter wound closure time, higher reepithelialization and less pain score were from the selected foam dressing compared to standard gauze soaked with chlorhexidine. This PU-alginate combined foam dressing adsorbed with asiaticoside and silver nanoparticles proved advantages for traumatic dermal wound management.

Keywords: Asiaticoside; Clinical efficacy; Polyurethane-alginate combined foam dressing.

MeSH terms

  • Animals
  • Dermis* / metabolism
  • Dermis* / microbiology
  • Dermis* / pathology
  • Drug Delivery Systems*
  • Drug Evaluation, Preclinical
  • HEK293 Cells
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Pneumococcal Infections* / drug therapy
  • Pneumococcal Infections* / metabolism
  • Pneumococcal Infections* / microbiology
  • Pneumococcal Infections* / pathology
  • Polyurethanes* / chemistry
  • Polyurethanes* / pharmacokinetics
  • Polyurethanes* / pharmacology
  • RAW 264.7 Cells
  • Streptococcus pneumoniae / metabolism*
  • Triterpenes* / chemistry
  • Triterpenes* / pharmacokinetics
  • Triterpenes* / pharmacology
  • Wound Infection* / drug therapy
  • Wound Infection* / metabolism
  • Wound Infection* / microbiology
  • Wound Infection* / pathology
  • Wounds and Injuries* / drug therapy
  • Wounds and Injuries* / metabolism
  • Wounds and Injuries* / microbiology
  • Wounds and Injuries* / pathology

Substances

  • Polyurethanes
  • Triterpenes
  • asiaticoside